In the study using transferred autologous T-cells transduced with a T-cell receptor (TCR) directed against NY-ESO-1, clinical response was observed in four of six patients (67%) with synovial sarcoma and five of 11 patients (45%) with melanoma bearing tumors-expressing NY-ESO-1 [114]. This evidence concerns the gene CTAG1B and synovial sarcoma.